Skip to main content
Premium Trial:

Request an Annual Quote

Micronoma, University of New South Wales to Develop Liver Cancer Dx Using $4M Grant

NEW YORK – Microbial cancer detection firm Micronoma said Tuesday that it is collaborating with the University of New South Wales, Sydney under a $4 million grant from the Australian government to apply artificial intelligence technology toward developing microbial biomarkers for the early detection of liver cancer.

Amany Zekry and Emad El-Omar, both professors at UNSW Medicine & Health, are leading the effort alongside co-principal investigator and Micronoma CSO Eddie Adams.

The group will use Micronoma's AI-driven microbial biomarker technology to detect, validate, and translate blood-borne microbial-derived biomarkers for the early detection of HCC — something the company has already been working on internally.

Micronoma CEO Sandrine Miller-Montgomery said in a statement that interest in the link between circulating microbiome signatures and cancer early detection has been growing since the firm's proof-of-concept publication in Nature last year.

"Developing a method to enable the identification of robust microbial plasma biomarker signatures of HCC is in our product pipeline, and this collaboration enables us to fast-track product development," she added.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.